Mer­ck dis­card jumps straight to the top of the chart of the most ex­pen­sive drugs in the US at $1M-plus

Back late last fall, when Eiger Phar­ma­ceu­ti­cals $EIGR com­plet­ed its vic­to­ry lap with an old Mer­ck dis­card it had de­vel­oped for rare cas­es of prog­e­ria, the com­pa­ny told re­porters that it was think­ing of pric­ing the new­ly dubbed Zok­in­vy at the usu­al rate re­served for ul­tra rare dis­eases. Mer­ck aban­doned the drug years ago af­ter giv­ing up on a can­cer in­di­ca­tion, and let Eiger have it for Prog­e­ria sev­er­al years ago with­out tack­ing on any mile­stones in the deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER